Verséa Health, Inc. - Verséa
 
HomeAuthor

Verséa Health, Inc.

2 new COVID symptoms reported for BA.2 omicron variant

According to recent reports, the new BA.2 COVID-19 variant (a subvariant of the omicron variant called BA.1.) spreads more easily than the original omicron. Early data suggest that BA.2 is about 30% more transmissible than the original variant. The new BA.2 variant can also manifest different symptoms than the original strains. New symptoms include: Dizziness Fatigue...

Omicron variants – Statement from the WHO

Yesterday the WHO’s Technical Advisory Group on SARS-Cov-2 Virus Evolution (ATG-VE) published a statement on new omicron variants that have been circulating globally, accounting for nearly all sequences reported to GISAID: “Based on available data of transmission, severity, reinfection, diagnostics, therapeutics and impacts of vaccines, the group reinforced that the BA.2 sublineage should continue to...

New Study Identifies Top-Performing Point-of-Care COVID-19 Tests

Researchers screen rapid-detection COVID-19 tests for sensitivity/specificity, limit of detection, and time to results ANN ARBOR, MI, and VANCOUVER, BC—February 10, 2021—After screening more than 1,100 independently assessed, point-of-care COVID-19 tests, researchers at NSF International and Novateur Ventures have identified five direct (antigen/RNA) tests for detection of acute infection and six indirect (antibody) tests for...

Collaboratively administrate turnkey channels whereas virtual e-tailers. Objectively seize scalable metrics whereas proactive e-services. Dynamically procrastinate B2C users after installed base benefits. Dramatically visualize customer directed convergence without revolutionary ROI.